Download Image
    
Share
  
Post
Alunacedase alfa for COVID-19
1 study with 178 patients
Hospital Icon Control
Hospital Icon Alunacedase alfa Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Alunacedase alfa studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -31% Mortality -31% RCTs -31% Late -31% Favorsalunacedase alfa Favorscontrol
Alunacedase alfa (APN01) is a recombinant soluble ACE2 biologic that acts as a decoy receptor and RAS-modulating enzyme to potentially neutralize SARS-CoV-2 and mitigate COVID-19 lung injury.
Dec 26
2020
 Bundgaard et al., NCT04335136 Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
31% higher mortality (p=0.61) and 23% lower ventilation (p=0.64). RCT 181 hospitalized COVID-19 patients showing no significant improvement with alunacedase alfa.